Evaluation of the Incidence of Choline-PET Detected Nodal Metastases Among Newly Diagnosed Prostate Cancer Patients With Presumed Absence of Nodal and Distant Metastases.
N/A
N/A
Male
Prostate Cancer
Trial Information
Evaluation of the Incidence of Choline-PET Detected Nodal Metastases Among Newly Diagnosed Prostate Cancer Patients With Presumed Absence of Nodal and Distant Metastases.
Inclusion Criteria:
- Consenting patients
- Diagnosed prostate cancer
Exclusion Criteria:
- Metastatic disease at presentation
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
Detection of Choline-PET detected nodal metastases
Outcome Description:
At the time of diagnosis of prostate cancer, the investigators intend to utilize Choline-PET scan to gain evidence of nodal metastatic disease with a motive to assess for a potentially higher sensitivity than with the use of conventional imaging methods such as CT or MRI.
Outcome Time Frame:
Eligible participants will undergo a Choline-PET scan before the initiation of any cancer specific treatments, that is within a time frame of one week from the time of diagnosis
Safety Issue:
No
Principal Investigator
Ajaikumar Basavalingaiah, MD
Investigator Role:
Study Chair
Investigator Affiliation:
HealthCare Global- Bangalore Insititute of Oncology
Authority:
India: Institutional Review Board
Study ID:
Choline-Prostate-1
NCT ID:
NCT01769950
Start Date:
January 2013
Completion Date:
February 2014
Related Keywords:
- Prostate Cancer
- Choline PET
- Choline PET-CT
- Positron emission tomography
- Prostate cancer
- Neoplasm Metastasis
- Prostatic Neoplasms
Name | Location |
|---|
